Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Cote d'Ivoire
Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Cote d'Ivoire
复制标题
DOI:
10.1016/j.trstmh.2005.11.008
复制
发表时间:
2006-08-01
影响因子:
2.2
通讯作者:
Anglaret, Xavier
中科院分区:
文献类型:
--
作者:
Toure, Siaka;Gabillard, Delphine;Anglaret, Xavier
In a placebo-controlled trial of co-trimoxazole prophylaxis in Cote d'lvoire, neutropenia was the most frequent short-term side effect. The long-term incidence of neutropenia in sub-Saharan African adults receiving co-trimoxazole has never been reported. We followed a prospective cohort of HIV-infected adults receiving co-trimoxazole (sulphamethoxazole 800 mg/trimethoprim 160 mg daily) in Abidjan. Grades of neutropenia were successively defined as at least one absolute neutrophil count (ANC) of: = 1), = 2), = 3) or = 1, 0.64 (95% Cl 0.60-0.71) for grade >= 2, 0.82 (95% Cl 0.77-0.86) for grade >= 3 and 0.96 (95% Cl 0.93-0.99) for grade 4. The only factor significantly associated with a higher rate of all grades of neutropenia was a tow baseline CD4 count. There was no association between any grade of neutropenia and the global risk of serious morbidity during the study period. In adults receiving co-trimoxazole in Abidjan, mild neutropenia is a common observation with no evidence of negative clinical consequences. The consequences of associating co-trimoxazole with other haematotoxic drugs should be carefully assessed. (C) 2006 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.